NEW YORK (TheStreet) -- CHANGE IN RATINGS
downgraded at Goldman from Buy to Neutral. Estimates also cut, as promotional activity may increase in the women's sector.
upgraded at BofA/Merrill to Buy from Neutral. Share price drop after the announced acquisition of Hewitt presents buying opportunity, Bank of America/Merrill Lynch said. Maintain $45 price target.
downgraded at BofA/Merrill to Underperform from Neutral as regional gaming revenues have slowed in 2Q10, Bank of America/Merrill Lynch said. Price target sunk to $11 from $20.
initiated at BofA/Merrill with an Underperform rating and $10 price target. Street is over optimistic on margins targets.
upgraded at BofA/Merrill to Buy from Neutral. Expecting bizjet recovery and 787 production ramp-up. Maintain $75 price target.
( CPNO) downgraded at UBS from Buy to Neutral. $26 price target. Company will like post weak second quarter results.
downgraded at Stifel from Buy to Hold. Company is seeing lower sales across the board.
upgraded at FBR from Market Perform to Outperform. $39 price target. Company has a strong balance sheet and should benefit from an improving macro environment.
initiated at Credit Suisse with an Outperform rating and $73 price target. FMC's significantly improved returns and quality of its portfolio offer a solid balance of growth and cash generation.
( HEW) downgraded at Deutsche from Buy to Hold. $48 price target. See limited chance for a competing bid to AON's offer.
Illinois Tool Works
upgraded at Deutsche from Hold to Buy. $59 price target. Core revenue growth should outperform the sector.
rated new Outperform at RBC Capital Markets. $45 price target. Stock has been hit of late, but remains attractively valued, given the normalized earnings potential.
Pharmaceutical Product Development
( PPDI) upgraded at Goldman to Buy. $31 price target. Estimates also boosted, given higher sales expectations.
upgraded at Morgan Stanley from Equal-weight to Overweight. $22 price target. Company is leveraged to increasing spot rates.
( SVR) rated new Buy at Goldman. $26 price target. Company should benefit from continued growth in mobile data growth.
upgraded at BofA/Merrill to Buy from Neutral. Valuation call. Maintain $25 price target.
downgraded at Goldman from Buy to Neutral. Valuation call. Estimates also lowered, because of macro growth risks.
STOCK COMMENTS / EPS CHANGES
estimates lowered at UBS through 2011. Company is seeing lower aluminum prices. Neutral rating and $12.85 price target.
More on Alcoa Why Investors Should Avoid Alcoa
target upped at Goldman to $81. Company is a potential takeover target. Buy rating.
target reduced at Goldman to $24. Europe continues to weigh on business. Neutral rating.
estimates increased at UBS through 2011. Company is guiding toward better results, aided by lower costs. Buy rating and $95 price target.
estimates, target cut at Goldman. Shares of EBAY now seen reaching $23. Estimates also reduced, given slower international growth and lower U.S. conversion rates. Neutral rating.
estimates, target cut at UBS. FCS estimates were lowered through 2011. Growth could moderate in the near term. Buy rating and new $12 price target.
numbers raised at UBS. Shares of NVLS now seen reaching $29.50. Estimates also increased, as orders should improve in the second half of the year. Neutral rating.
numbers lowered at Goldman. RCL estimates were cut through 2012. Company will likely see lower net yields. Neutral rating and new $25 price target.
estimates, target reduced at UBS. Shares of SHAW now seen reaching $38. Estimates also lowered, to reflect the company's lower backlog. Neutral rating.
target cut at Goldman. Shares of WYNN now seen reaching $88. Multiple could contract in the volatile market environment. Neutral rating.
This article was written by a staff member of TheStreet.